Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.

[1]  D. Kerr,et al.  Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: A phase IIb randomized trial. , 2019, Molecular genetics and metabolism.

[2]  C. Siffel,et al.  Epidemiology of Sanfilippo syndrome: results of a systematic literature review , 2018, Orphanet Journal of Rare Diseases.

[3]  C. Hendriksz,et al.  Mortality in patients with Sanfilippo syndrome , 2017, Orphanet Journal of Rare Diseases.

[4]  Lidia Gaffke,et al.  How close are we to therapies for Sanfilippo disease? , 2017, Metabolic Brain Disease.

[5]  P. Haslett,et al.  A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. , 2016, Molecular genetics and metabolism.

[6]  P. Haslett,et al.  A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA. , 2016, The Journal of pediatrics.

[7]  P. Haslett,et al.  Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome. , 2013, JIMD Reports.

[8]  T. Shimada,et al.  Newborn screening and diagnosis of mucopolysaccharidoses. , 2013, Molecular genetics and metabolism.

[9]  M. Heartlein,et al.  Safety evaluation of chronic intrathecal administration of heparan N-sulfatase in juvenile cynomolgus monkeys , 2012, Drug Delivery and Translational Research.

[10]  R. Wevers,et al.  Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype‐phenotype correlations , 2010, Annals of neurology.

[11]  Anthony O. Fedele.  The Application of Clinical Genetics Dovepress Sanfilippo Syndrome: Causes, Consequences, and Treatments , 2022 .